ID: ALA4560733

Max Phase: Preclinical

Molecular Formula: C20H16Cl2N2OS

Molecular Weight: 403.33

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C(Nc1cc(Cl)cc(Cl)c1)N1CCc2sccc2C1c1ccccc1

Standard InChI:  InChI=1S/C20H16Cl2N2OS/c21-14-10-15(22)12-16(11-14)23-20(25)24-8-6-18-17(7-9-26-18)19(24)13-4-2-1-3-5-13/h1-5,7,9-12,19H,6,8H2,(H,23,25)

Standard InChI Key:  OUAZBTMDKBUPEM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.33

Molecular Weight (Monoisotopic): 402.0360

AlogP: 6.23

#Rotatable Bonds: 2

Polar Surface Area: 32.34

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.74

CX Basic pKa:

CX LogP: 5.99

CX LogD: 5.99

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.54

Np Likeness Score: -1.94

References

1. Wortmann L, Lindenthal B, Muhn P, Walter A, Nubbemeyer R, Heldmann D, Sobek L, Morandi F, Schrey AK, Moosmayer D, Günther J, Kuhnke J, Koppitz M, Lücking U, Röhn U, Schäfer M, Nowak-Reppel K, Kühne R, Weinmann H, Langer G..  (2019)  Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo.,  62  (22): [PMID:31670515] [10.1021/acs.jmedchem.9b01382]

Source

Source(1):

• Scientific Literature